GSK reported core earnings of 59 cents per American ... owing to strong growth in all regions. Sales of Anoro Ellipta declined 2%. Key established drug Advair/Seretide sales declined 2%, while ...

GSK chief executive Andrew Witty told investors ... bringing in £11 million and Anoro (umeclidinium and vilanterol) just £5 million, respectively 32 and 35 per cent shy of analyst predictions.

GSK has a further study, IMPACT, which compares the new closed triple therapy with dual combinations Breo and Anoro, which is set to produce results in 2017. However the FULFIL study could be ...

Our model suggests Trelegy Ellipta, Breo Ellipta and Anoro Ellipta sales to be around £596 million, £280 million and £138 million, respectively. GSK’s key vaccine, Shingrix’s, sales showed ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing ...